WQ
CORT icon

Wealth Quarterback’s Corcept Therapeutics CORT Stock Holding History

Wealth Quarterback’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,039
Closed -$452 – 1004
2019
Q4 		$452 Buy
+6,039
New +$84.1K ﹤0.01% 915

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Wealth Quarterback's CORT Position: Q1 2020 in Review

Wealth Quarterback sold out of Corcept Therapeutics (CORT) in Q1 2020, closing a stake of 6,039 shares — an estimated $452 sold.

Wealth Quarterback first reported a position in CORT in Q4 2019 and held it in 1 quarter. The position peaked at $452 in Q4 2019. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

  • Wealth Quarterback reported no remaining Corcept Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Wealth Quarterback sold 6,039 Corcept Therapeutics shares in Q1 2020, an estimated $452.
  • Wealth Quarterback first reported a position in Corcept Therapeutics in Q4 2019 and held it in 1 quarter.
  • Wealth Quarterback's Corcept Therapeutics position peaked at $452 in Q4 2019.
  • 204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on Wealth Quarterback's 13F filing for Q1 2020, filed 14 May 2020.